[Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].

Mil'chakova, A E; Popov, G R; Bykov, A V; Gekht, A B

Mil'chakova, A E; Popov, G R; Bykov, A V; Gekht, A B.

Zh Nevrol Psikhiatr Im S S Korsakova ; 108(4): 49-55, 2008.

Article in Ru | MEDLINE | ID: mdl-18567194

Subject(s)

Antiparkinson Agents/economics; Antiparkinson Agents/therapeutic use; Economics, Pharmaceutical/statistics & numerical data; Parkinson Disease/drug therapy; Piribedil/economics; Piribedil/therapeutic use; Costs and Cost Analysis; Humans; Parkinson Disease/economics; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Piribedil / Economics, Pharmaceutical / Antiparkinson Agents Type of study: Health_economic_evaluation Limits: Humans Language: Ru Journal: Zh Nevrol Psikhiatr Im S S Korsakova Journal subject: NEUROLOGIA / PSIQUIATRIA Year: 2008 Document type: Article

Search on Google

Add to My VHL

XML

PubMed Links